Alumis Inc. Common Stock (ALMS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 227
- Market Cap
- $3.7B
About Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
SentiSense also tracks daily options readings for Alumis Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Alumis Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.